Wird geladen...
Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings
BACKGROUND: The most common site of disease in metastatic castration‐resistant prostate cancer (mCRPC) is the bone. The ALSYMPCA study demonstrated that radium‐223 significantly improved overall survival (OS) in mCRPC patients with symptomatic bone metastases and without visceral metastases. However...
Gespeichert in:
| Veröffentlicht in: | Prostate |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8251844/ https://ncbi.nlm.nih.gov/pubmed/33978244 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.24143 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|